ASTELLAS PHARMA

🇯🇵Japan
Ownership
-
Established
2005-01-01
Employees
-
Market Cap
$22.5B
Website
https://www.astellas.com/

To Compare the Efficacy and Safety of a Therapy of Tacrolimus With Sirolimus or MMF in Kidney Transplantation.

Phase 3
Completed
Conditions
Interventions
First Posted Date
2006-02-27
Last Posted Date
2014-09-01
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
634
Registration Number
NCT00296361

Comparing Efficacy & Safety of Tacrolimus & MMF With/Without Induction in the Elderly Following Kidney Transplantation.

Phase 3
Completed
Conditions
Interventions
First Posted Date
2006-02-27
Last Posted Date
2014-09-01
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
267
Registration Number
NCT00296309

Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.

Phase 3
Completed
Conditions
Interventions
First Posted Date
2006-02-24
Last Posted Date
2014-08-26
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
627
Registration Number
NCT00295594

A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis

Phase 3
Completed
Conditions
First Posted Date
2006-02-20
Last Posted Date
2007-12-24
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
645
Registration Number
NCT00293930

A Study to Assess the Long-Term Safety of Tacrolimus Cream in the Treatment of Psoriasis

Phase 3
Completed
Conditions
First Posted Date
2006-02-20
Last Posted Date
2008-02-13
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
658
Registration Number
NCT00293917

A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis

Phase 3
Completed
Conditions
First Posted Date
2006-02-20
Last Posted Date
2007-12-24
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
658
Registration Number
NCT00293891

Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

First Posted Date
2006-02-01
Last Posted Date
2024-10-21
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
112
Registration Number
NCT00285259
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Baylor University Medical Center, Dallas, Texas, United States

and more 19 locations

A Double-blind, Group-comparison Study Using Zolpidem (Myslee) as a Comparative Drug in Patients With Insomnia

First Posted Date
2006-01-31
Last Posted Date
2014-08-20
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
876
Registration Number
NCT00283946
© Copyright 2024. All Rights Reserved by MedPath